Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs
Leerink Swann Upgrades Medicines Company To Outperform
Related BMY
Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman
10 Biotech Stories You Might've Missed This Week
Apple Leads the Charge as Earnings Season Heats Up (Fox Business)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News


Related Articles (MDCO + BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters